** Shares of cancer therapy maker Novocure NVCR.O up 2% at $16.84 premarket
** Company posts Q2 revenue of $158.8 million, compared with analysts' average expectations of $154.2 million - data compiled by LSEG
** J.P.Morgan says Q2 revenue "driven primarily by active patient growth across major markets"
** Novocure plans to submit a premarket approval application to the FDA for pancreatic cancer treatment in Q3 2025
** "We believe it may take getting closer to meaningful rev growth from these new opportunities for the stock to work," JPM adds
** Up to last close, stock down 44.6% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.